Delcath Systems, Inc. (NASDAQ:DCTH) Financial Performance and Competitive Analysis
- Delcath Systems, Inc. (NASDAQ:DCTH) has a Return on Invested Capital (ROIC) of 3.58%, indicating it is not covering its cost of capital.
- Cyclacel Pharmaceuticals and Rennova Health show significant inefficiencies in capital utilization with negative ROIC values.
- ImmunoCellular Therapeutics demonstrates exceptional capital efficiency with an ROIC of 1,140.12% and the highest ROIC to WACC ratio among peers.
Delcath Systems, Inc. (NASDAQ:DCTH) is a medical device company focused on oncology, developing the Delcath Hepatic Delivery System for high-dose chemotherapy administration to the liver. The company competes in a challenging landscape alongside Cyclacel Pharmaceuticals, Interpace Biosciences, and ImmunoCellular Therapeutics.
In evaluating Delcath's financial performance, the Return on Invested Capital (ROIC) of 3.58% is crucial, yet it falls short of its Weighted Average Cost of Capital (WACC) of 7.61%, signaling that Delcath is not generating sufficient returns to cover its cost of capital. This poses a concern for investors.
Comparatively, Cyclacel Pharmaceuticals exhibits a negative ROIC of -336,215.88% against a WACC of 4.70%, leading to a highly unfavorable ROIC to WACC ratio. This indicates Cyclacel's significant underperformance in capital efficiency. Conversely, Interpace Biosciences shows a positive ROIC of 84.16% with a WACC of 9.00%, resulting in a favorable ROIC to WACC ratio of 9.36.
ImmunoCellular Therapeutics stands out with an impressive ROIC of 1,140.12% and a WACC of 15.35%, achieving the highest ROIC to WACC ratio of 74.29 among its peers. This efficiency in utilizing capital to generate returns marks ImmunoCellular as a strong performer in the group.
Aeterna Zentaris and Rennova Health both display negative ROICs of -21.44% and -12.76%, respectively, with WACCs of 14.71% and 8.68%. Their ROIC to WACC ratios of -1.46 and -1.47, respectively, highlight inefficiencies in capital utilization, mirroring the challenges faced by Delcath.
| Symbol | Price | %chg |
|---|---|---|
| 048260.KQ | 1901000 | 0 |
| 214150.KQ | 50200 | -1.79 |
| 287410.KQ | 12900 | 0 |
| 085370.KQ | 36700 | 0 |
Delcath Systems, Inc. (NASDAQ:DCTH) Financial Performance and Competitive Landscape
Delcath Systems, Inc. (NASDAQ:DCTH) is a medical technology company focused on oncology. It develops and commercializes therapies for the treatment of primary and metastatic liver cancers. The company's main product is the Hepatic Delivery System, which administers high-dose chemotherapy to the liver while minimizing systemic exposure. Delcath operates in a competitive landscape with peers like Interpace Biosciences, EOM Pharmaceuticals Holdings, Aeterna Zentaris, and Rennova Health.
In evaluating Delcath's financial performance, the Return on Invested Capital (ROIC) is a key metric. Delcath's ROIC is 3.58%, which is lower than its Weighted Average Cost of Capital (WACC) of 7.61%. This indicates that Delcath is not generating enough returns to cover its cost of capital, which can be a concern for investors looking for efficient capital use.
Comparatively, Interpace Biosciences shows a positive ROIC of 84.16% with a WACC of 9.41%, leading to a favorable ROIC to WACC ratio of 8.94, indicating better capital efficiency than Delcath.
EOM Pharmaceuticals Holdings stands out with an impressive ROIC of 1,140.12% and a WACC of 16.82%, resulting in a ROIC to WACC ratio of 67.77. This suggests that EOM is generating returns far above its cost of capital, highlighting strong capital efficiency and potential for growth. In contrast, Aeterna Zentaris and Rennova Health both have negative ROICs, indicating challenges in generating sufficient returns on their invested capital.
Delcath Systems, Inc. (NASDAQ:DCTH) Financial Performance and Competitive Landscape
Delcath Systems, Inc. (NASDAQ:DCTH) is a medical technology company focused on oncology. It develops and commercializes proprietary therapies to treat primary and metastatic liver cancers. The company's main product is the Hepatic Delivery System, which administers high-dose chemotherapy to the liver while minimizing systemic exposure. Delcath operates in a competitive landscape with peers like Interpace Biosciences, and Aeterna Zentaris.
In evaluating Delcath's financial performance, the Return on Invested Capital (ROIC) is a key metric. Delcath's ROIC is 3.58%, which is lower than its Weighted Average Cost of Capital (WACC) of 7.54%. This indicates that Delcath is not generating sufficient returns to cover its cost of capital, which can be a concern for investors looking for efficient capital use.
Comparatively, Interpace Biosciences shows a positive ROIC of 84.16% with a WACC of 9.04%, leading to a favorable ROIC to WACC ratio of 9.31, indicating better capital utilization.
EOM Pharmaceuticals Holdings stands out with an impressive ROIC of 1,140.12% and a WACC of 18.16%, resulting in the highest ROIC to WACC ratio of 62.77 among its peers. This suggests EOM is highly efficient in using its capital to generate returns, making it a potentially attractive investment. Meanwhile, Aeterna Zentaris and Rennova Health both have negative ROICs, indicating challenges in generating returns above their respective costs of capital.
Delcath Systems, Inc. (NASDAQ:DCTH) Q2 2025 Earnings Overview
- Earnings Per Share (EPS) of $0.07 exceeded estimates, marking a significant turnaround from the previous year's loss.
- Revenue of approximately $24.16 million surpassed estimates, driven largely by the HEPZATO KIT™ sales.
- Despite challenges in profitability, Delcath maintains a strong financial position with a low debt-to-equity ratio and a high current ratio.
Delcath Systems, Inc. (NASDAQ:DCTH) is an interventional oncology company that focuses on treating primary and metastatic liver cancers. The company recently reported its Q2 2025 earnings, showcasing a strong performance. Delcath's earnings per share (EPS) of $0.07 exceeded the estimated $0.02, marking a significant improvement from the previous year's loss of $0.48 per share. This earnings surprise of 250% highlights the company's positive trajectory.
The company's revenue for the quarter was approximately $24.16 million, surpassing the estimated $23.02 million. This represents a 9.3% increase over the Zacks Consensus Estimate and a substantial rise from the $7.77 million reported in the same quarter last year. Delcath's revenue growth is largely driven by the HEPZATO KIT™, which contributed $22.5 million, up from $6.6 million the previous year.
Despite these positive results, Delcath Systems faces some challenges. The enterprise value to operating cash flow ratio is significantly negative at -51.99, highlighting difficulties in generating positive cash flow from operations.
However, Delcath maintains a strong financial position with a low debt-to-equity ratio of 0.013, suggesting minimal reliance on debt financing. The company's current ratio of 15.95 indicates a robust ability to cover short-term liabilities with short-term assets. This financial stability provides a solid foundation for future growth and development in the competitive medical instruments industry.
